BPC-157 47 min read January 28, 2026

Peptide Research and Gut Inflammatory Disorders

## What is the difference between IBD and IBS? Inherently, IBD is an organic disease, as evidenced by mucosal inflammation, whereas IBS lies more in the spectrum of a functional disorder, with no evidence of organic disease. IBS symptoms are nonspecific and may precede diagnosis of both IBS and IBD by many years. See the Venn diagram below to understand the relationship among IBD and IBS.

Peptide Research and Gut Inflammatory Disorders

Irritable Bowel Syndrome (IBS)

Irritable bowel syndrome (IBS) is a chronic disorder of the gastrointestinal tract, characterized by abdominal pain and alterations in bowel habits. IBS is the disorder most commonly encountered by gastroenterologists, and diagnosis is made according to a symptom-based classification system, the Rome Criteria, with the latest version, Rome IV, recently released (Drossman, 2016). Prevalence rates in North America have been reported as approximately 12%, and symptoms occur more often in patients less than 50 years of age.

Patients with IBS suffer not only from gastrointestinal distress, but approximately 40–60% experience comorbid psychological disorders, such as depression or anxiety. In addition, patients with IBS report higher levels of somatization compared to patients without IBS but with gastrointestinal symptoms. Not surprisingly, IBS has been shown to negatively impact patients’ quality of life, as well as to adversely affect society’s financial resources.

Despite the substantial cost of IBS to both patients and society, curative, medical interventions have yet to be discovered. The development and persistence of IBS symptoms have been acknowledged as multifactorial in nature, making treatment of the disorder a complicated, clinical endeavor. Approaches are based on the reduction of patient symptomatology, and current pharmacological management often provides suboptimal relief.

Evidence of biological dysregulation has been reported in patients with IBS, and efforts are ongoing to advance understanding of the neurohormonal underpinnings of the disorder. Although gains have been made in understanding the pathophysiology of IBS, exact mechanisms leading to symptom development are not completely understood.

Inflammatory bowel disease (IBD)

The inflammatory bowel diseases primarily include Crohn’s disease and ulcerative colitis. Crohn’s disease is an IBD that causes inflammation anywhere along the lining of the digestive tract, while ulcerative colitis causes long-lasting inflammation in some part of the digestive tract (mainly the colon). The exact etiology of IBD is not well known.

There are several factors that have been postulated to influence the development of this group of diseases, which include but are not limited to bacterial contamination, a change in the immune system, and genetic variations. For instance, a mutation in the _NOD2_ gene is associated with an increased susceptibility to IBD via production of proinflammatory cytokines. While genetic predisposition plays a key role in immune-mediated diseases, the major influence appears to be due to environmental factors.

Current research suggests that autoimmune diseases are most prevalent in highly industrialized nations but rare in less developed countries. Moreover, studies have shown that increased consumption of milk protein, animal protein, and polyunsaturated fatty acids can increase the risk for IBD, and that consumption of tobacco increases the risk of Crohn’s disease.

The major subtypes of IBD, including Crohn’s disease and ulcerative colitis, have a high prevalence rate in the world, with North America noting the highest frequency of people suffering with Crohn’s disease. In addition, statistics show that an estimated 129,000 people live with the disease in Canada. Although the onset of the disease usually occurs during adulthood, children are increasingly being diagnosed with IBD.

Treating IBD often involves use of medications that can diminish the symptoms and decrease the inflammation in the colon lining. A group of anti-inflammatory drugs including 5-aminosalicylic acid is commonly used to treat IBD. Other drugs such as infliximab are also indicated in patients who have failed conventional therapy and are hospitalized with severe IBD. Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α), a cytokine involved in intestinal inflammation.

Several other immunomodulatory drugs, such as thalidomide, can also be used to treat a patient with severe IBD. Formerly used as a sedative and hypnotic, this synthetic drug has been shown to significantly reduce the inflammation associated with IBD. However, under certain circumstances, when medical therapy fails, surgery may be considered. This operation is known as colectomy and involves removal of the large intestine. While ulcerative colitis is cured upon removal of the colon, Crohn’s disease unfortunately can still recur after surgery.

While medication is commonly used to treat IBD, most pharmaceutical compounds have side effects such as headache, diarrhea, and nausea, which can reduce patient compliance and result in worsening of the condition. Therefore, different approaches to therapy like the use of peptides, can provide promising results for those who have gut inflammatory disorders.

What is the difference between IBD and IBS?

Inherently, IBD is an organic disease, as evidenced by mucosal inflammation, whereas IBS lies more in the spectrum of a functional disorder, with no evidence of organic disease. IBS symptoms are nonspecific and may precede diagnosis of both IBS and IBD by many years.

See the Venn diagram below to understand the relationship among IBD and IBS.

What is KPV Peptide?

α-MSH is a neurohormone with extensive immunomodulatory effects on certain cell types. It exhibits potent anti-inflammatory effects by binding to melanocortin receptors in the skin. It is reported that the anti-inflammatory activity of α-MSH is mediated by the three terminal amino acids, Lysine-Proline-Valine (KPV).

KPV lacks the entire sequence motif required for binding to the MC-Rs, but still retains almost all the anti-inflammatory capacity of the parent hormone. This is also because peptides (like KPV) often act as hormones and relay information from one tissue through the blood to another _via_ biologic messengers. The inflammatory activity of KPV is suggested to be mediated _via_ inhibition of interleukin (IL)-1β.

Unlike α-MSH, KPV is free from the melanotropic effects and thus does not cause any pigmentation. Additionally, it is smaller in size and more chemically stable than α-MSH. These attributes make KPV a suitable candidate for the treatment of inflammatory skin disorders. KPV has a molecular weight of 383.49 Da and an Isoelectric point (pI) of 14 and hydrophilic in nature.

KPV is more stable and exerts less side effects, as it shares its sequence with human proteins. KPV might therefore be an interesting, easy to produce, and inexpensive therapeutic option in the treatment of inflammatory bowel disease that must be elucidated in future clinical trials.

Research Example #1:

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

Background: Despite some progress in recent years, the options for treating inflammatory bowel disease (IBD) are still dissatisfying, and surgery rates are still high. The anti-inflammatory effects of melanocortin peptides such as alpha-melanocyte-stimulating hormone (alpha-MSH) have been described recently in, for example, dextran sodium sulfate (DSS) colitis in mice. The aim of this study was to investigate the therapeutic potential of the melanocortin-derived tripeptide alpha-MSH(11-13) (KPV) and its mode of action in 2 models of intestinal inflammation.

Methods: The anti-inflammatory activity of KPV was analyzed in 2 well-described models of IBD: DSS colitis, and CD45RB(hi) transfer colitis. Furthermore, animals expressing a nonfunctional melanocortin-1 receptor (MC1Re/e) received DSS for induction of colitis and were treated with KPV. The course of inflammation was monitored by weight loss and histological changes in the colon as well as by myeloperoxidase (MPO) activity.

Results: In the DSS-colitis model, treatment with KPV led to earlier recovery and significantly stronger regain of body weight. Histologically, inflammatory infiltrates were significantly reduced in KPV-treated mice, which was confirmed by the significant reduction of MPO activity in colonic tissue after KPV treatment. Supporting these findings, KPV treatment of transfer colitis led to recovery, regain of body weight, and reduced inflammatory changes histologically. In MC1Re/e mice, KPV treatment rescued all animals in the treatment group from death during DSS colitis.

Conclusions: The melanocortin-derived tripeptide KPV showed significant anti-inflammatory effects in 2 murine models of colitis. These effects seem to be at least partially independent of MC1R signaling. In conclusion, our data suggest KPV as an interesting therapeutic option for the treatment of IBD.

Research Example #2:

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

Background & aims: KPV is a tripeptide (Lys-Pro-Val), which possesses anti-inflammatory properties; however, its mechanisms of action remain unknown. PepT1 is a di/tripeptide transporter normally expressed in the small intestine and induced in colon during inflammatory bowel disease (IBD). The aim of this study was to 1) investigate whether the KPV anti-inflammatory effect is PepT1-mediated in intestinal epithelial and immune cells, and 2) examine the anti-inflammatory effects in two models of mice colitis.

Methods: Human intestinal epithelial cells Caco2-BBE, HT29-Cl.19A, and human T cells (Jurkat) were stimulated with pro-inflammatory cytokines in the present or absence of KPV. KPV anti-inflammatory effect was assessed using a NF-kappaB luciferase gene reporter, Western blot, real-time RT-PCR and ELISA. Uptake experiments were performed using cold KPV as a competitor for PepT1 radiolabeled substrate or using [(3)H] KPV to determine kinetic characteristics of KPV uptake. Anti-inflammatory effect of KPV was also investigated in DSS- and TNBS-induced colitis in mice. KPV was added to drinking water and inflammation was assessed at the histologic level and by proinflammatory cytokine mRNA expression.

Results: Nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways and reduce pro-inflammatory cytokine secretion. We found that KPV acts via PepT1 expressed in immune and intestinal epithelial cells. Furthermore, oral administration of KPV reduces the incidence of DSS- and TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression.

Conclusions: This study indicates that KPV is transported into cells by PepT1 and might be a new therapeutic agent for IBD.

What is BPC-157 Peptide?

BPC 157 is a penta-decapeptide containing a partial sequence of the body protection compound (BPC) isolated from the human gastric juice]. It is stable and resistant to hydrolysis or digestion by enzymes. Previous studies have demonstrated the promoting effect of BPC 157 on the healing of different tissues, including skin, mucosa, cornea, muscle, tendon, ligament and bone in animal studies. The mechanism by which penta-decapeptide BPC 157 accelerates healing is not clearly understood. It has been suggested to include up-regulation of growth factors, proangiogenic effect, and modulation of nitric oxide (NO) synthesis. BPC 157 may also control functions of collagen fragments that are associated with bone morphogenic proteins.

Research Example #1:

Stable gastric penta-decapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat

Purpose: Gastric penta-decapeptide BPC 157 (BPC 157), which has been shown to be safe in clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia), may be able to cure intestinal anastomosis dehiscence. This antiulcer peptide shows no toxicity, is limit test negative, and a lethal dose is not achieved. It is stable in human gastric juice. In comparison with other standard treatments, it is more effective for ulcers and various wounds, and can be used without a carrier needed for other peptides, both locally and systemically (i.e., perorally, parenterally). We studied the effectiveness of BPC 157 for ileoileal anastomosis healing in rats.

Methods: We assessed ileoileal anastomosis dehiscence macroscopically, histologically, and biomechanically (volume [ml] infused through a syringe-perfusion pump system (1 ml/10 s), and pressure [mmHg] to leak induction [catheter connected to a chamber and a monitor, at 10 cm proximal to anastomosis]), at 1, 2, 3, 4, 5, 6, 7, and 14 days. BPC 157 (10 microg, 10 ng, 10 pg/kg i.p. (or saline [5 ml/kg]) was first administered after surgery, while it was last given 24 h before either assessment or sacrifice.

Results: Throughout the experiment, both higher doses of BPC 157 were shown to improve all parameters of anastomotic wound healing. The formation of adhesions remained slight, the blood vessels were filled with blood, and a mild intestinal passage obstruction was only temporarily observed. Anastomosis without leakage induces markedly higher volume and pressure values, with a continuous increase toward healthy values. From day 1, edema was markedly attenuated, and the number of granulocytes decreased, while from days 4 or 5 necrosis decreased and granulation tissue, reticulin, and collagen formation substantially increased, thus resulting in increased epithelization.

Conclusion: This study showed BPC 157 to have a beneficial effect on ileoileal anastomosis healing in the rat.

Research Example #2:

Penta-decapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats

Besides a superior protection of the penta-decapeptide BPC 157 (an essential fragment of an organ protective gastric juice peptide BPC) against different gastrointestinal and liver lesions, an acute anti-inflammatory and analgetic activity was also noted. Consequently, its effect on chronic inflammation lesions, such as adjuvant arthritis, and non-steroidal anti-inflammatory agents (NSAIAs)-induced gastrointestinal lesions was simultaneously studied in rats. In gastrointestinal lesions (indomethacin (30 mg/kg sc), aspirin (400 mg/kg ig) and diclofenac (125 mg/kg ip) studies, BPC 157 (10 μg or 10 ng/kg ip) was regularly given simultaneously and/or 1 h prior to drug application (indomethacin). In the adjuvant arthritis (tail-application of 0.2 mL of Freund's adjuvant) studies (14 days, 30 days, 1 year) BPC 157 (10 μg or 10 ng/kg ip), it was given as a single application (at 1 h either before or following the application of Freund's adjuvant) or in a once daily regimen (0–14th day, 14–30th day, 14th day–1 year). Given with the investigated NSAIAs, BPC 157 consistently reduced the otherwise prominent lesions in the stomach of the control rats, as well as the lesions in the small intestine in the indomethacin groups. In the adjuvant arthritis studies, the lesion's development seems to be considerably reduced after single penta-decapeptide medication, and even more attenuated in rats daily treated with BPC 157. As a therapy of already established adjuvant arthritis, its salutary effect consistently appeared already after 2 weeks of medication, and it could be clearly seen also after 1 year of application. Taking together all these results, the data likely point to a special anti-inflammatory and mucosal integrity protective effect.

What is VIP Peptide?

Vasoactive intestinal peptide (VIP) is a 28-residue amino acid peptide first characterized in 1970 that was initially isolated from porcine duodenum. A member of the secretin/glucagon hormone superfamily VIP is evolutionarily well conserved with sequence similarity among fish, frogs, and humans; among mammals, except for guinea pigs and chickens, the sequence similarity is at least 85%.

VIP was initially discovered owing to its potent vasodilatory effects (as its name implies). VIP is widely distributed in the central and peripheral nervous system as well as in the digestive, respiratory, reproductive, and cardiovascular systems as a neurotransmitter and neuroendocrine releasing factor. These effects contribute to an extensive range of physiological and pathological processes related to development, growth, and the control of neuronal, epithelial, and endocrine cell function. VIP has also been implicated in the regulation of carcinogenesis, immune responses, and circadian rhythms.

How does VIP work?

The two receptors that recognize VIP, termed VPAC1 and VPAC2, are class B of G-protein-coupled receptors (GPCRs), also known as the secretin receptor family, which includes receptors for VIP, PACAP, secretin, glucagon, glucagon-like peptide (GLP)-1 and -2, calcitonin, gastric inhibitory peptide (GIP), corticotropin-releasing factor (CRF)-1 and -2, and parathyroid hormone (PTH). VPAC1 and VPAC2 are activated by VIP and PACAP, whereas PACAP has its own specific receptor, named PAC1, for which VIP has very low affinity. Through these receptors, VIP can mediate an extensive number of GI functions such as regulating gastric acid secretion, intestinal anion secretion, enzyme release from the pancreas, cellular motility, vasodilation, and intestinal contractility. The localization of VIP, VPAC1, and VPAC2 is closely related to their physiological and pathological functions.

Research Example #1:

Vasoactive intestinal peptide decreases inflammation and tight junction disruption in experimental necrotizing enterocolitis

Background and Purpose

Excessive inflammatory cell infiltration and accumulation in the intestinal mucosa are pathological features of necrotizing enterocolitis (NEC) leading to intestinal barrier disruption. Vasoactive intestinal peptide (VIP) is a potent anti-inflammatory agent that regulates intestinal epithelial barrier homeostasis. We previously demonstrated that VIP-ergic neuron expression is decreased in experimental NEC ileum, and this may be associated with inflammation and barrier compromise. We hypothesize that exogenous VIP administration has a beneficial effect in NEC.

Methods

NEC was induced in C57BL/6 mice by gavage feeding, hypoxia, and lipopolysaccharide administration between postnatal day (P) 5 and 9. There were four studied groups: _Control_ (n = 6): Breast feeding without stress factors; _Control + VIP_ (n = 5): Breast feeding + intraperitoneal VIP injection once a day from P5 to P9; _NEC_ (n = 9): mice exposed to NEC induction; _NEC + VIP_ (n = 9): NEC induction + intraperitoneal VIP injection. Terminal ileum was harvested on P9. NEC severity, intestinal inflammation, (IL-6 and TNFα), and Tight junctions (Claudin-3) were evaluated.

Results

NEC severity and intestinal inflammation were significantly decreased in NEC + VIP compared to NEC. Tight junction expression was significantly increased in NEC + VIP compared to NEC.

Conclusion

VIP administration has a beneficial therapeutic effect in NEC by reducing inflammation and tight junction disruption.

Research Example #2:

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system

Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions that in turn regulate ion secretion, nutrient absorption, gut motility, glycemic control, carcinogenesis, immune responses, and circadian rhythms. Genetic ablation of this peptide and its receptors in mice also provides new insights into the contribution of VIP towards physiological signaling and the pathogenesis of related diseases. Here, the researchers discuss the impact of VIP on gastrointestinal function and diseases based on recent findings, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.

References:

Product available for research use only:

Posted in: BPC-157 KPV VIP

Be the first to know

Receive all the latest information on events, sales, & offers.

Terms and Conditions of Purchase

Your Use of Our Web Site

Unless specified otherwise, your use of this Web Site is governed by this Terms and Conditions of Use Agreement and the Privacy Policy, which is incorporated herein by this reference. In using this Web Site, you are prohibited from modifying, distributing, transmitting, reproducing, publishing, licensing, transferring, or selling any information, products or services obtained or viewed on this Web Site. However, you may display, download, or print hard copies of any material contained on this Web Site for your own personal, non-commercial use as long as you do not modify the content or delete any copyright, trademark, or other proprietary notice. Any other use of the information contained on this Web Site is prohibited without our express written consent.

All ACH/e-Check payments will be made payable to:

P-Sciences, Inc.

Each time I (the customer) places an ACH/e-Check order by clicking the "Place Order" button, I am authorizing to initiate a single ACH/electronic debit to my account in the amount of my order from the bank account information provided on the date of my order. I agree that ACH transactions I authorize comply with all applicable law. Payments made after 11 P.M. pacific time will be applied as of the next business day. To complete the payment process, click the “Place Order” button. Once payment is authorized, there cannot be any changes or corrections. It is recommended that you print a copy of this authorization and maintain it for your records.

Use of Information

This Web site provides information that, while useful, must not be used as a substitute for the advice of your own advisors. Information available from this Web Site is not intended to be used to diagnose any medical condition or disease. Products on this website are sold for laboratory research purposes only.

reserves the right to correct any inaccuracies or typographical errors in the information posted on this Web Site, and shall have no liability for such errors. Information may be changed or updated without notice and prices and availability of goods and services are subject to change without notice.

DISCLAIMER:

YOU MUST BE OVER 21 YEARS OLD TO USE THIS WEBSITE.

The products we offer are intended for IN-VITRO LABORATORY RESEARCH USE ONLY-- NOT FOR HUMAN USE.

In purchasing any of these items, the customer acknowledges that there are risks involved with consumption or distribution of these products.

These chemicals are NOT intended to use as food additives, drugs, household chemicals or other inappropriate applications.

The listing of a material on this site does not constitute a license to its use in infringement of any patent.

All of the products will be handled only by qualified and properly trained RESEARCH or LABORATORY professionals only.

Due to the nature of these products ALL SALES ARE FINAL. WE CANNOT ACCEPT RETURNS. ALL SALES ARE FINAL.

All customers represent and warrant that through their own review and study that they are fully aware and knowledgeable about the following:

Use of the products and more specifically In-vitro Research use of the products.

Your specific countries Government regulations regarding the use of and exposure to all products.

The health and safety hazards associated with the handling of the products they purchase.

The necessity of adequately warning of the health and safety hazards associated with any products.

reserves the right to limit and/or deny sales of products to any unqualified individuals. All customers MUST be at least 21 years of age to purchase our products. IN NO CIRCUMSTANCE SHALL BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER PURCHASER'S CLAIM IN CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE. IN DIRECT CONSIDERATION OF APPROVING THE SALE OF ANY PRODUCT TO THE PURCHASER, THE PURCHASER AGREES TO INDEMNIFY AND HOLD US HARMLESS FROM ALL CLAIMS, EXPENSES, LOSSES AND LIABILITY OF ANY TYPE ARISING OUT OF THE PURCHASER'S HANDLING, POSSESSION, AND/OR USE OF THE PRODUCT, WHETHER USED ALONE OR IN COMBINATION WITH ANY SUBSTANCE. ANY SALE WOULD BE DENIED OTHERWISE.

PRODUCT USE:

products are intended for laboratory IN-VITRO RESEARCH PURPOSES ONLY-- NOT FOR HUMAN USE and are not to be used for any other purposes, including but not limited to food and/or drugs, medical devices, vitro diagnostic purpose, or for commercial purposes. The purchaser agrees that the products have not been sterilized or tested by for safety and efficacy in food, drug, medical device, cosmetic, commercial or any other use. The purchaser expressly represents and warrants to that the purchaser will properly test, use, manufacture and market any products purchased from and/or materials produced with products purchased from in accordance with the practices of a reliable person who is experienced in the field and in strict compliance with all applicable laws and regulations, now and hereinafter enacted. The purchaser further warrants that any material produced with any product shall not be adulterated or misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act and shall not be materials which may not, under Sections 404, 505, or 512 of the Act, be introduced into interstate commerce.

The purchaser realizes that, since products are, unless otherwise stated, intended solely for in-vitro research purposes, they may not be on the Toxic Substances Control Act (TSCA) inventory listing. The purchaser assumes responsibility to assure that the products purchased from are approved for use under TSCA, if applicable.

Purchaser has the responsibility to verify the hazards and to conduct any further research necessary to learn the hazards involved in using products purchased from Purchaser agrees to comply with instructions, if any, furnished by relating to the use of the products and not misuse the products in any manner. No products purchased from shall, unless otherwise stated, be considered to be foods, drugs, or medical devices.

ALL products and services offered are for IN-VITRO RESEARCH purposes ONLY and are NOT TO BE INGESTED or CONSUMED IN ANY MANNER.

ALL PRODUCTS SOLD BY THE ARE NOT TO BE USED FOR PERSONAL USE OR FOR THE TREATMENT OF ANY MEDICAL CONDITION OR DISEASE.

Under NO circumstances shall/ should ANY of these materials be used for recreational purposes nor human consumption of any kind.

is NOT liable for ANY damages that may be caused by negligence, abuse, or ANY other unforeseen matter.

All items sold are legal for sale for IN-VITRO RESEARCH PURPOSES SPECIFICALLY within the USA.

Trade-Marks and Other Intellectual Property Rights

"" is a registered trademark of

All text, graphics, user interfaces, visual interfaces, photographs, trademarks, logos, sounds, music, artwork and computer code (collectively, "Content"), including but not limited to the design, structure, selection, coordination, expression, "look and feel" and arrangement of such Content, contained on this Web Site is owned, controlled or licensed by or to and is protected by copyright, patent and trademark laws, and various other intellectual property rights and unfair competition laws.

Except as expressly provided in this Terms and Conditions of Use Agreement, no part of this Web Site and no Content may be copied, reproduced, republished, uploaded, posted, publicly displayed, encoded, translated, transmitted or distributed in any way (including "mirroring") to any other computer, server, web site or other medium for publication or distribution or for any commercial enterprise, without express prior written consent.

Indemnity

You hereby agree to indemnify and hold and our subsidiaries, affiliates, officers, directors, agents, co-branders, partners, and employees harmless from any claim or demand, including reasonable attorney's fees, made by any third party due to or arising out of your use of the content on this Web Site, or any content you submit, post, or transmit through this Web Site, your use of this Web Site, your connection to this Web site, your violation of this Terms and Conditions of Use Agreement, or your violation of any rights of another.

Links/Software

Links from or to websites outside this Web Site are meant for convenience only. does not review, endorse, approve or control, and is not responsible for any sites linked from or to this Web Site, the content of those sites, the third parties named therein, or their products or services. Linking to any other site is at your sole risk and will not be responsible or liable for any damages in connection with linking. disclaims all warranties, express and implied as to the accuracy, validity and legality of any materials or information found on those sites. Links to downloadable software sites are for convenience only and is not responsible or liable for any difficulties or consequences associated with downloading the software. Use of any downloaded software is governed by the terms of the license agreement, if any, which accompanies or is provided with the software.

Availability of Our Web Site

This Web Site is generally available to users Twenty-four (24) hours per day, Seven (7) days per week, Three Hundred Sixty-five (365) days per year. However, retains the right to make our Web Site unavailable at any time, for any reason, and for any length of time. By using this Web Site you agree that will not be liable for any damage arising out of or related to any such interruption, suspension, or termination of this Web Site and/or the services or products contained therein. Upon acceptance of these terms and conditions of use authorizes you to view the Content on the Web Site solely for your personal use. The material on the Web Site is intended solely for individuals enquiring about products or services. If you are not accessing the Web Site for such purposes, you may not use the Web Site. For certainty, use by non-individuals or the agents, attorneys or representatives of non-individuals is prohibited.

**Information You Provide

Our collection and/or use of any information you provide while using or visiting this Web Site is governed by the Privacy Policy and this Terms and Conditions of Use Agreement. By using this Web Site you grant us the rights contained therein. In using this Web Site you may not upload, distribute, or otherwise publish on this Web Site any information which may be viewed as obscene, defamatory, libelous, threatening, abusive, illegal, an invasion of privacy rights, or otherwise objectionable, or may constitute or encourage a violation of any law.

Except for that individually-identifiable information collected from you in accordance with our Privacy Policy, all comments, remarks, suggestions, ideas or other information communicated will become the exclusive property of and you grant to a royalty-free, perpetual, irrevocable, world-wide, non-exclusive license to use or reproduce the same. is free to copy, disclose, distribute or analyze any such information for any and all purposes and are in no way obligated to compensate you for any such information.

Disclaimer of Warranties

PROVIDES CONTENT ON THIS WEB SITE AS A SERVICE TO YOU, OUR CUSTOMER. THIS WEB SITE CANNOT AND DOES NOT, CONTAIN INFORMATION ABOUT ALL APPLICATIONS FOR PRODUCTS SOLD. IT MAY NOT CONTAIN ALL INFORMATION THAT IS APPLICABLE TO YOUR PERSONAL CIRCUMSTANCES OR YOUR USE OF PRODUCTS SOLD. THE CONTENT OF THIS WEB SITE, THE WEB SITE SERVER THAT MAKES IT AVAILABLE, AND THE SERVICES AND PRODUCTS PROVIDES ON THIS WEB SITE, ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS WITHOUT WARRANTY OF ANY KIND, WHETHER EXPRESS, IMPLIED OR STATUTORY. EXPRESSLY DISCLAIMS LIABILITY FOR TECHNICAL FAILURES (INCLUDING HARDWARE OR SOFTWARE FAILURES), INCOMPLETE, SCRAMBLED OR DELAYED COMPUTER TRANSMISSIONS, AND/OR TECHNICAL INACCURACIES, AS WELL AS UNAUTHORIZED ACCESS OF USER TRANSMISSIONS BY THIRD PARTIES. FURTHER, DOES NOT REPRESENT OR WARRANT THAT NO VIRUSES OR OTHER CONTAMINATING OR DESTRUCTIVE PROPERTIES WILL BE TRANSMITTED, OR THAT NO DAMAGE WILL OCCUR TO YOUR COMPUTER SYSTEM. YOU HAVE SOLE RESPONSIBILITY FOR ADEQUATE PROTECTION AND BACKUP OF DATA AND/OR EQUIPMENT AND TO TAKE ALL PRECAUTIONS TO SCAN FOR COMPUTER VIRUSES OR OTHER DESTRUCTIVE PROPERTIES. BY YOUR USE OF THIS WEB SITE, YOU ACKNOWLEDGE THAT SUCH USE IS AT YOUR SOLE RISK, INCLUDING RESPONSIBILITY FOR ALL COSTS ASSOCIATED WITH ALL NECESSARY SERVICING OR REPAIRS OF ANY EQUIPMENT YOU USE IN CONNECTION WITH THIS WEB SITE.

TO THE FULL EXTENT NOT PRECLUDED BY APPLICABLE LAW THEIR MEDICAL ADVISORS, SUPPLIERS, CONSULTANTS, DIRECTORS AND EMPLOYEES DISCLAIM AND EXCLUDE ALL WARRANTIES WITH RESPECT TO ALL CONTENT, EXPRESS, IMPLIED OR STATUTORY. THIS DISCLAIMER INCLUDES, BUT IS NOT LIMITED TO, ANY AND ALL WARRANTIES OR MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT. DOES NOT WARRANT THE CONTENT TO BE ACCURATE, COMPLETE OR CURRENT. DOES NOT WARRANT THAT THIS WEB SITE WILL OPERATE WITHOUT ERROR, THAT DEFECTS WILL BE CORRECTED OR THAT THIS WEB SITE OR THE WEB SITE SERVER MAKING IT AVAILABLE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. PRICE AND AVAILABILITY CONTENT, AS WELL AS OTHER CONTENT CONTAINED IN THIS WEB SITE OR ACCESSIBLE THEREFROM, IS SUBJECT TO CHANGE WITHOUT NOTICE.

YOU ACKNOWLEDGE AND AGREE THAT DOES NOT ENDORSE THE CONTENT OF ANY SITE ACCESSED VIA LINKS OR OTHER MEANS FROM THIS WEB SITE AND IT IS NOT RESPONSIBLE OR LIABLE FOR SUCH CONTENT EVEN THOUGH IT MAY BE UNLAWFUL, HARASSING, LIBELOUS, PRIVACY INVADING, ABUSIVE, THREATENING, HARMFUL, OBSCENE, OR OTHERWISE OBJECTIONABLE, OR THAT IT INFRINGES OR MAY INFRINGE THE INTELLECTUAL PROPERTY OR OTHER RIGHTS OF ANOTHER PERSON.

THIS WEB SITE INCLUDES CONTENT PROVIDED BY THIRD PARTIES AND YOU, OUR CUSTOMER. IS A DISTRIBUTOR OF SUCH CONTENT AND NOT ITS PUBLISHER. EDITORIAL CONTROL OF SUCH CONTENT IS THE SAME AS THAT OF A PUBLIC LIBRARY OR NEWSSTAND. THIRD PARTY SUPPLIERS MAY EXPRESS CERTAIN OPINIONS OR PROVIDE CERTAIN INFORMATION AND OFFERS. MAKES NO WARRANTIES AS TO THE COMPLETENESS, ACCURACY, TIMELINESS, OR RELIABILITY OF INFORMATION OR OFFERS SUPPLIED BY THIRD PARTIES. DOES NOT GUARANTEE OR WARRANT THE PERFORMANCE OF ANY THIRD PARTY, INCLUDING ANY SUCH THIRD PARTY’S CONFORMANCE TO ANY LAW, RULE, REGULATION OR POLICY.

DOES NOT WARRANT THAT INFORMATION, SERVICES, AND PRODUCTS CONTAINED IN THIS WEB SITE WILL SATISFY YOUR REQUIREMENTS OR THAT THEY ARE ERROR OR DEFECT-FREE. BEFORE USING ANY PRODUCT YOU SHOULD CONFIRM ANY INFORMATION OF IMPORTANCE TO YOU ON THE PRODUCT PACKAGING. YOU ASSUME RESPONSIBILITY FOR THE ACCURACY, APPROPRIATENESS AND LEGALITY OF ANY INFORMATION YOU SUPPLY

AS PARTIAL CONSIDERATION FOR YOUR ACCESS TO THIS WEB SITE AND USE OF ITS CONTENT, YOU AGREE THAT IS NOT LIABLE TO YOU IN ANY MANNER WHATSOEVER FOR DECISIONS YOU MAY MAKE OR YOUR ACTIONS OR NON-ACTIONS IN RELIANCE UPON THE CONTENT. YOU ALSO AGREE THAT THE AGGREGATE LIABILITY OF ARISING FROM OR RELATED TO YOUR USE AND ACCESS REGARDLESS OF THE FORM OF ACTION OR CLAIM (FOR EXAMPLE, CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY, PROFESSIONAL MALPRACTICE, FRAUD, OR OTHER BASES FOR CLAIMS), IS LIMITED TO THE PURCHASE PRICE OF ANY ITEMS YOU PURCHASED FROM IN THE APPLICABLE TRANSACTION. SHALL NOT IN ANY CASE BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES EVEN IF HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS IS A COMPREHENSIVE LIMITATION OF LIABILITY THAT APPLIES TO ALL LOSES AND DAMAGES OF ANY KIND. IF YOU ARE DISSATISFIED WITH THIS WEB SITE OR ITS CONTENT (INCLUDING TERMS OF USE), YOUR SOLE EXCLUSIVE REMEDY IS TO DISCONTINUE USING THIS WEB SITE. BECAUSE SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, SUCH LIMITATION MAY NOT BE APPLICABLE TO YOU.

Your Agreement to Abide by All Applicable Laws

By using this Web Site you agree to comply with any and all local, state, or federal laws, statutes, and regulations that relate in any manner to the use of this Web Site and the associated services or products contained thereon.

Relationship between and Users.

and users of our Site are independent contractors, and no agency, partnership, employment or other relationship is created or is intended to be created by the use of our Web Site.

Governing Law and Jurisdiction

This Web Site (excluding linked sites, if any) is administered and controlled by and its affiliates, subsidiaries, officers, directors, employees or agents from its offices in the accordance with the laws of Nevis. You agree that this Terms and Conditions of Use Agreement and this Web Site will be governed by and construed in accordance Nevis law without giving effect to any principles of conflicts of laws. You access this Web Site and/or associated services of at your own risk, and remain responsible for complying with the laws of the jurisdiction within which you are located.

Prices; Payment Terms; Interest

The prices for the products and services on this Web Site are quoted, for convenience, in United States dollars and shall be as set forth in this Web Site as at the time of acceptance of an order by Prices for Products shall be subject to change without any further notice. Credit terms are within sole discretion, and unless otherwise specified in invoice, payment must be received by prior to acceptance of an order.

Consequences

reserves the right to suspend or terminate your account if you violate the Terms of Use Agreement. If your violation causes harm to others, you agree to indemnify and hold harmless from and against any and all loss, damage, or expense. If any dispute arises between us regarding this Agreement or your use of this Web Site, it shall be resolved through good faith negotiations between the parties.

Entire Agreement

These Terms and Conditions and any terms incorporated or referred to herein constitute the entire agreement between and you relating to your use of this Web Site and the subject matter hereof, and supersede any prior understandings or agreements (whether electronic, oral or written) regarding the subject matter, and may not be amended or modified except in writing, or by making such amendments or modifications in accordance with this Terms and Conditions of Use Agreement.

Severability

If any part of this Terms and Conditions of Use Agreement is deemed or determined to be unenforceable, then such part shall be eliminated or limited to the minimum extent necessary. The remainder of this Terms and Conditions of Use Agreement, including any revised portion, shall remain and be in full force and effect. This Terms and Conditions of Use Agreement are the entire agreement between us governing your use of this Web Site.

Headings

The headings contained in this Terms and Conditions of Use Agreement and the Privacy Policy are for reference only.

Force Majeure

shall not be liable for any delay or failure in performance caused by circumstances beyond its reasonable control, including, without limitation, delays due to backorders of requested products, mail delays, customs delays or lost shipments. shall not be responsible to notify the Customer in the event of such delays. The Customer shall be solely responsible to make other arrangements to purchase alternative products and any costs incurred in connection with such purchases.

Thank you again for visiting the Web Site.

Complete Agreement

Except as expressly provided in a particular "legal notice" on this Site, these Terms and Conditions constitute the entire agreement between you and this Site with respect to the use of this Site, and Content. By clicking “I agree” when placing your order, you agree with ALL OF OUR TERMS and CONDITIONS as stated above as well as our Shipping and refunds Policy.

Thank you for your cooperation.

Terms and Conditions of Purchase

Your Use of Our Web Site

Use of Information

DISCLAIMER:

Shipping address will be selected within Apple Pay. Any address entered in checkout will not be used.